Jiang, Ruixuan
Shaw, James
Mühlbacher, Axel
Lee, Todd A.
Walton, Surrey
Kohlmann, Thomas
Norman, Richard
Pickard, A. Simon http://orcid.org/0000-0001-5645-7091
Funding for this research was provided by:
EuroQol Research Foundation
Bristol-Myers Squibb
Article History
Accepted: 13 November 2020
First Online: 28 November 2020
Compliance with ethical standards
:
: RJ is a member of the EuroQol group and an employee of Merck. This work was completed prior to beginning her position at Merck during her graduate studies. During her graduate studies, she was supported by Fellowships from the University of Illinois at Chicago and the PhRMA Foundation. This work was previously presented at a EuroQol group meeting, for which RJ was awarded a travel scholarship to attend. JWS is an employee and shareholder of Bristol-Myers Squibb. TAL is a partner in Second City Outcomes Research LLC, which has received consulting fees and payment for expert testimony from the pharmaceutical/device industry. ASP is a member of the EuroQol group, developers of the EQ-5D, a non-profit Dutch registered charity. ASP is a partner in Second City Outcomes Research LLC, which has received consulting fees from industry.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.